Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Data from Two Phase 3 Studies of DEXYCU
to be presented at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting
WATERTOWN, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced multiple data presentations at upcoming industry medical conferences. Details of each presentation can be found below:
2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
An oral presentation and a poster highlighting long-term, 36- and 24-month data of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg, the Company's three-year micro-insert for chronic non-infectious uveitis affecting the posterior segment of the eye, have been accepted for presentation at the ARVO 2019 Annual Meeting being held April 28 - May 2, 2019, in Vancouver, British Columbia. Presentation details below:
Title: Treatment of Non-infectious Uveitis that Affects the Posterior Segment with a Single Intravitreal Fluocinolone Acetonide Insert (FAi) - 3-year Results
Presenter: Glenn J. Jaffe, MD, Robert Machemer Professor of Ophthalmology, Duke Eye Center
Session Title: Uveitis Clinical Epidemiology and Therapeutics
Data and Time: Tuesday, April 30, 2019 at 4:00 - 4:15 PM PT
Title: Minimizing Recurrences of Ocular Inflammation and Need for Adjunctive Treatment of Non-infectious Posterior Uveitis (NIPU) during the 2 Years Following Treatment with a Single 0.18 mg Fluocinolone Acetonide Intravitreal Insert (FAi)
Session Title: Uveitis and Scleritis - Clinical Therapeutics and Checkpoint Inhibitors
Data and Time: Tuesday, April 30, 2019 at 11:45 AM - 1:30 PM PT
2019 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA)Annual Meeting
A poster highlighting DEXYCU™ (dexamethasone intraocular suspension) 9%, the Company's single dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation following cataract surgery, has been accepted for presentation at the ASCRS ASOA 2019 Annual Meeting being held May 3-7, 2019 in San Diego, California. Presentation details below:
Title: Effect of Dexamethasone Intraocular Suspension 9% on IOP after Cataract Surgery: Results of Two Phase 3 Studies
Session Title: SPS-301 Inflammation, Pain, Infection
Data and Time: Monday, May 6, 2019 at 8:07 - 8:12 AM PT
YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye, and was approved by the FDA on October 12, 2018. A link to the full product label is available on the EyePoint Pharma website at: www.eyepointpharma.com/wp-content/uploads/2019/01/YUTIQ-USPI-20181120.pdf.
DEXYCUTM (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation and was approved by the FDA on February 9, 2018. A link to the full product label is available at: https://dexycu.com/wp-content/uploads/2019/01/DEXYCU-PI-20181220.pdf.
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) (www.eyepointpharma.com), headquartered in Watertown, MA, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has two products, YUTIQ™ and DEXYCU™, that were approved by the U.S. Food and Drug Administration in 2018 and have been launched directly in the U.S. during the first quarter of 2019.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the closing of the proposed offering, as well as the anticipated use of proceeds for the proposed offering and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint's actual results to be materially different than those expressed in or implied by EyePoint's forward-looking statements. For EyePoint, this includes satisfaction of the customary closing conditions to the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility, the impact of general business and economic conditions, the expected gross proceeds from the offering and the intended use of proceeds of the offering. More detailed information on these and additional factors that could affect EyePoint's actual results are described in EyePoint's filings with the Securities and Exchange Commission, including its transition report on Form 10-K for the six month transition period ended December 31, 2018, its most recent annual report on Form 10-K for the fiscal year ended June 30, 2018 and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: EyePoint Pharmaceuticals, Inc.